Speakers

josko bobanovicJosko Bobanovic
Joško Bobanović joined Sofinnova in 2010 as Partner dedicated to activities in renewable chemistry and industrial biotech. Prior to joining Sofinnova he spent eight years in venture capital with iNovia Capital and its fund MSBi Capital in Montreal, Canada. Joško was responsible for cleantech investments at the fund, and focused on seed and early stage investments in cleantech and information technology. Prior to his venture capital career he created an internet startup and a software company. After completing his PhD studies Joško developed real-time ocean forecasting systems still used at Environment Canada for coastal ocean management. Joško holds a BSc. in physics from University of Zagreb, a PhD in physical oceanography from Dalhousie University and an MBA in finance and marketing from McGill University.

pawel bochniarzPaweł Bochniarz
• Serial entrepreneur, adviser, mentor and expert in commercialization of new technologies
• Alumnus of Economics studies at the Warsaw University and postgraduate studies - Advanced Management Program on IESE Business School. Expert and adviser experienced within the field of startups creation and acceleration.
• Board chairman of MIT Enterprise Forum Poland and coordinator of Acceleration Program for technological projects realized by this organization
• Previously, i.a. Innovation Advisory Director at PwC, co-founder of Coalition For Polish Innovations

joseph borgJohn J Borg
Pharmacist, specialised in Pharmacology currently serves as a Director at the Maltese Medicines Agency (ADM) and is responsible for EU centralised medicinal product evaluations; scientific advice and clinical trials at the Maltese Medicines Agency. Prof. Borg’s professional trajectory has touched several areas of expertise from pre-clinical study to clinical activity as well as R&D of Ion Channel modulators, along with his commitment to teaching and regulatory activity, such as: national and international regulatory activities for the European union; preparation, evaluation and coordination of Research Projects; participation in international bodies etc. Maltese member of the Committee for Human Medicinal Products (CHMP); member of the Committee on Advanced therapies (CAT); member of the Pharmacovigilance Risk Assessment Committee (PRAC); Member of the Paediatric Committee (PDCO); Co-Chair of the European Union Pharmacovigilance Oversight Group and member of the biologics working party (BWP) at the European Medicines Agency. John J Borg trained at the University of Bristol and has published numerous scientific publications as well as chapters in books.

marek borzestowskiMarek Borzestowski
Marek Borzestowski is a CEO of NanoGroup, a holding of biotechnology companies. He is an entrepreneur, manager and founder of numerous innovative companies with over 20 years of experience as a co-owner and board member in leading Polish biotech, IT, and e-commerce companies. After over a decade working as a CEO of a first internet portal in Poland – Wirtualna Polska, he established Polish Israeli VC Giza Polish Ventures. He is a founder of a think tank Sobieski Institute, Startup Hub Poland Foundation. He is a supervisory board member in numerus innovative companies. Marek graduated from the Faculty of Management and Economics at the Gdańsk University of Technology, he also studied at the University of Wales in Great Britain. He conducted a scientific research at the Nuclear Research Center in Karlsruhe and Technical University of Gdansk.

artur chabowskiArtur Chabowski
He is a specialist with over 20 years of experience in the field of international investment banking.
His career started in the Ministry of Ownership Transformations, later he worked i.a. at CAIB Financial Advisers, KPMG, ABN AMRO Corporate Finance and ACADIA. Mr Artur Chabowski is a graduate of the Faculty of Organisation and Management at the Warsaw University of Technology, moreover,
he completed post-graduate studies at the University of Princeton in the Woodrow Wilson School
of Public & International Affairs. He has been associated with Mabion and the life science industry since 2009.

Steffen HeegerSteffen Heeger
Dr. Steffen Heeger joined Selvita in February 2018 and is responsible for all clinical , medical affairs and regulatory functions for Selvita oncology pipeline. Dr. Steffen Heeger is an oncologist with a thorough experience in oncology drug development. Prior to joining Selvita, Dr. Heeger held a position of Vice President, Head of Clinical Development and Head of Clinical Operations at Morphosys AG, where he focused on the development and execution of clinical strategy for Morphosys’ lead hematology and oncology products. Dr. Heeger’s previous experience includes also nine-year tenure at Merck Serono, where he was Head of Medical Affairs and led the Global Clinical Development Team for Erbitux®. Dr. Heeger studied Medicine in Freiburg, Heidelberg and Mannheim and continued his medical training at the Department of Hematology and Oncology of the University Hospital in Heidelberg. Simultaneously with his medical training as a Physician, he also held the position of a Scientist at the German Cancer Research Center (DKFZ) in Heidelberg where he worked on the development of antibody conjugates. He received a PhD in Medicine from the University of Heidelberg.

kevin johnsonKevin Jonson
Prior to co-founding medicxi, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Kevin spearheaded Index’s very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He is currently chairman of Levicept Ltd., Apcintex and Crescendo Biologics as well as being a board member of several other startups.
Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now on the market: Humira (Abbott Pharmaceuticals) and Benlysta (GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.
Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD from Cambridge University.

roland kozlowski fotRoland Kozłowski
Roland received a first class hon¬ours degree from the University of Bath and a PhD from the University of Cambridge. He is a serial bio-entrepreneur, investor and mentor who has worked in the industry for over twenty five years. Roland was Chief Executive Officer of Lec-tus Therapeutics and Sense Proteomic Limited two venture capital backed companies which he founded, built and sold. During his career Roland has lead or played a key role in a many transactions including company financing, sale, purchase, financing and in- and out-licensing with a cumulative value of over $200m. Earlier in his career Roland ran Research Groups at the University of Oxford and University of Bristol where he published and patented in the life science field. He has been a Visiting Industrial Professor, served on, or advised the boards of several European companies and organizations including the Bio-Industry Association in the UK. Presently he is President and owner of Life Science Biznes Consulting which specializes in commercializing technology from emerging economies particularly in Poland. He has acted as an advisor to the National Centre of Research & Development in Poland and the Polish Development Agency. He is a founder and limited partner in Life Science Innovations a specialist VC fund based in Poland and a director or mentor to a number of start-up companies.

robert moldachRobert Mołdach
Robert Mołdach, PhD (Eng), industry expert specializing in health care organization, organizational culture and business development strategies. Acquired management expertise from health care, telecommunications, IT, banking and finance sectors. Educator and promoter of dialogue. Partner and Chairman of the Board at the Institute for Health and Democracy, an advisory and analytical group promoting democratic dialogue on health, based on facts, arguments and scientific evidence.

edwin mosesEdwin Moses
Serial entrepreneur and value creator in European life science companies. As CEO built two businesses (Oxford Asymmetry International plc and Ablynx nv), led their successful IPOs on the LSE, EuroNext and NASDAQ and raised over €500M in equity and debt financing. Was responsible for developing the business plans and implementing them. Ran the sales process for Oxford Asymmetry generating £316M in value. With Ablynx he has secured a bid from Sanofi for the company of €3.9Bn – the transaction is expected to complete in the summer of 2018. Expertise in high value service provision to the pharmaceutical industry and in drug discovery and development. Primarily focussed on high growth businesses and change management. 25 years of Board level experience in more than 10 companies, mostly as Chairman.

Oliver MurphyOliver Murphy
Oliver has extensive experience in corporate finance consulting, due diligence, restructuring and integration, both in the UK and in Poland. He conducted fundraising processes for British and Polish innovative companies in the life science industry, and also he conducted many transactions in the broadly defined LSHC sector. Oliver is a leader in the Pharmaceutical and Healthcare sector at Deloitte. He is a graduate of the Faculty of Economics at the University of Manchester and a member of the Association of Chartered Accountants in England and Wales (ICAEW).

kreske nickelsenKreske Nickelsen
Ms Nickelsen is a venture capital professional with more than 18 years of supervisory board and investment experience in companies based all over Europe. Before JPIF, Ms Nickelsen was a partner at Aescap, a life science venture capital fund based in Amsterdam (www.Aescap.com), and before that a director at 3i Group plc in London (www.3igroup.com). She holds an MBA from INSEAD (France) and a Masters in Biology from Philipps University Marburg (Germany).

pawel nowickiPaweł Nowicki
Paweł Nowicki is co-founder and president of BTM Group which consists of business-technology consulting boutique, technology transfer support center and seed investment fund for early stage R&D projects. He managed nearly 100 consulting projects both for public and private sector, also co-created or invested in 20 startup companies. He is coordinator of Cluster BioTechMedMazovia and board member of Polish Clusters Association.

mariusz olejniczakMariusz Olejniczak
Mariusz Olejniczak, Inventor of MonitorCR and CEO of WPD Pharmaceuticals is an experienced professional in medicinal products, medical devices, supplements and plant protection products R&D at every stage - from planning and scientific advice through supervision to the closure and finalization of the project. He is a founder of MonitorCR and a member of the board and supervisory board of several R&D companies. He was also responsible for the acquisition of Bioscience SA. by the Neuca group. As a graduate in biotechnology at the University of Life Sciences in Poznań, he has developed his skills through postgraduate studies. He is author of the publication „Change of the product development model as an opportunity for the Polish pharmaceutical industry” (in Polish), a member of the editorial committee of the book „Clinical Trials” (in Polish) and a lecturer in post-graduate study programs and PhD student on Kozminski University.

Łukasz PartykaŁukasz Partyka
CEO & co-founder of KCRI – medical device oriented contract research organization. Lukasz is a vascular medicine physician and experienced project manager. And KCRI supports medical device manufacturers in bringing their innovation safely to market through well designed and executed clinical research programs. Except for market authorization studies KCRI screens and implements medical devices for possible use in clinical trial methodologies (remote sensors, decision support systems, remote consultations, etc.). Established in 2004, KCRI was instrumental in First-In-Human applications of complicated and invasive devices and also supported largest players on the market in their late, post-marketing strategies.

bassem salehBassem Saleh
Bassem is an experienced Hemato-oncologist and Pharmaceutical Medicine Consultant. He launched his medical career in frontline patient care and has more than a decade of experience in drug development. Bassem has been involved in designing and delivering a high number of haematology/oncology clinical trials, and programs involving many types of therapies including chemotherapies, radiotherapies, targeted therapies, immunotherapies, radio-immunotherapies, gene therapies and GMOs. Before joining TFS Bassem held senior medical affairs and leadership positions in several pharmaceutical companies and CROs. He played an integral part in the growth and success of these companies which include ICON, PRA and Premier Research. Bassem holds an MD, an FFPM and a CCT from the UK Faculty of Pharmaceutical Medicine of the Royal College of Physicians.

arkadiusz sitekArkadiusz Sitek
Arkadiusz Sitek, Ph.D., is a scientist working on research and development of artificial intelligence in radiology and healthcare. He received his doctorate degree in physics from the University of British Columbia, Canada, and since 1998 has worked in several academic institutions in the USA including Lawrence Berkeley National Laboratory, Beth Israel Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital and for more than ten years as a research professor in Harvard Medical School. He is currently employed by IBM Watson Health in Cambridge. He has authored more than 150 papers, books, book chapters, and patents and serves on the editorial board of Physics in Medicine and Biology.

justyna supelJustyna Supel
Justyna Supel is an experienced Operations and Compliance Executive with an excellent understanding of public funding processes in the commercial and public sector. Justyna obtained a Masters Degree in Biological Chemistry from the Jagiellonian University in Krakow, thereafter she worked in Poland and the UK as research scientist. Following receipt of an MBA from Oxford Brooks University, Justyna moved into the commercial sector where she was instrumental in raising grant funding and managing operations at Selvita. She also played a key role in raising public funds for and subsequent building of the Malopolska Centre of Biotechnology dealing with manyoperational, compliance, financial and legal issues. Presently she works for the Malopolska SPIN initiative seeking out investment opportunities from the Jagiellonian University and the Malopolska Region and subsequently providing assistance in business planning and development of funding strategies.Justyna is also R&D manager for Orion Biotechnology.

marcin szumowskiMarcin Szumowski
Marcin Szumowski is serial entrepreneur. He received his MS and PhD degrees from the University of Illinois and earned an MBA degree in entrepreneurship and international finance. Following a successful research career in the United States, Marcin has been involved in technology transfer and start-up companies since 2000 and has co-founded and managed five start-ups, including a medical diagnostics company Medicalgorithmics S.A. (www.medicalgorithmics.com), where he was President and CEO 2005-2011. Medicalgorithmics is present on 5 continents, has been listed on the Warsaw Stock Exchange and has reached a market cap of over $300M. Since 2013 Marcin is President & CEO of OncoArendi Therapeutics S.A. (www.oncoarendi.com), a Polish innovative biopharmaceutical company dedicated to developing and commercializing novel therapeutics for neoplastic, inflammatory and fibrotic diseases. In five years the company has grown to over 80 employees and raised over $65M research funding from private investors and public grants. OncoArendi was recently listed on the Warsaw Stock Exchange with IPO valuation of approx. $120 million. The company has assets in late phase I and in late preclinical development. Marcin is also one of co-founders and lead investors of the Life Science Innovations (LSI) seed fund. Since 2012 Marcin has assisted the European Commission on three independent expert panels performing the impact assessment, interim and final evaluations of the Innovative Medicines Initiative (IMI), the world’s largest public-private partnership (PPP) in pharmaceutical research. Over the last 20 years Marcin has managed over 50 R&D and investment projects with a total value well over $300M.

wtWojciech Tarnawski
Wojciech Tarnawski, M.Sc. Eng. degree in biomedical engineering and the Ph.D. degree in computer science from the Wrocław University of Technology, Wrocław, Poland. 19 years of experience as scientist at the faculty of Electronics, Wrocław University of Technology in image analysis and data mining. From 2010 to 2011- Postdoctoral Fellow at ETH Zurich granted by the Scientific Exchange Programme between Poland and Switzerland. Currently serial entrepreneur, especially focused on med-tech applications. Business and research interests include: computer vision, cloud computing, numerical simulations, data mining and their applications to biomedical engineering. Co-Founder at LifeFlow (CEO), MicroscopeIT and Vratis companies.

heiko visarius fotHeiko Visarius
Dr. Heiko Visarius is an executive with international experience in the health care sector, especially in the area of medical device technology. A Ph.D. in engineering obtained in the USA and a Swiss/US MBA degree combined with his professional experience allow him to relate to a broad spectrum of business areas, such as sales, marketing, R&D, finance, supply chain and general management. Dr. Heiko Visarius served as CEO of a successful start-up company with an associated exit. Since then, he held various leadership positions with global players of the medical device industry (Synthes/J&J, Medtronic). He had P/L responsibility in Europe for a 3-digit million USD revenue volume in a direct operation. Since 2012, he is owner of VISARTIS Healthcare GmbH. In addition, Dr. Visarius is board member of several Medtech companies as well as an international business school and serves on various expert boards, including Horizon2020 (European Community). He and his family are located in Switzerland.

nuno viegasNuno Viegas
Dr. Nuno Viegas has 16 years in innovation, including 5 years in large pharma and 3 years in leading roles in biotech start-ups. He was a Marie Curie Fellow and has received his PhD from Hannover Medical School during the MIDITRAIN program organized by the Helmholtz centre for infection research. Nuno has moved to the Netherlands in 2011 to work for Crucell B.V. as a scientific advisor. After transition of Crucell B.V. into Johnson and Johnson, he was the scientific advisor to the viral Janssen vaccines vice-president, responsible for external innovation and scientific advisor to a therapeutic vaccine program. He has received a Gold Encore award from Janssen for the submission and resulting approval of IND status for of a novel human therapeutic vaccine. After that, he has worked at the Business development department where he was responsible for evaluating many external opportunities, where he has lead several due diligences and has been involved in the strategy of the vaccine unit. In 2017 he was invited to be the Business Creation Manager of the European Innovation, Technology and Health Institute (EIT Health) where he supported the BP plan improvement of a large number of startups and provided funding to the most promising ones.

david vitaDavid Vita
Over 25 years of experience in managing startups as CEO and VPM&S. David is expert in training and escorting teams to success. Formerly PWC & McK Alumnus where he specialized in M&A for large food makers and energy companies in Europe. Owner of Makwa Ltd Consulting he lately has been active in Poland while co-founding a polish based biomed consulting company and before that a successful clean energy one. David’s companies went from the idea to exit and from receivership to become public in different sectors: IT Telecom and Biomed (examples: LeadIP Ltd, EVR Ltd, ECI Ltd., Nilimed and FLSN- TASE and TNOLF-NASDAQ). He also was in charge of strategic marketing for a USD600M telecom access division during its buyout and worked as a consultant in the fertilizers and in the food industry in Israel. David graduated from Haifa University in 1982. He also attended specialized courses in the field of management in Switzerland and in biotech at the San Diego University in California; he is fluent in Italian, French, English and Hebrew. In the 90ies David has opened and managed the Massachusetts State and Port Authorities Office of Business Development in Israel for 3 consecutive appointments - nine years. His work supported the establishment of a branch in the New England for over 80 Israeli hi-tech companies and helped others develop sales channels in Israel and Jordan.

Simon WallworkSimon Wallwork
Simon Wallwork is a partner of Slater Heelis, Solicitors, based in Manchester, UK.and leads its Corporate Team. With over 30 years experience advising on acquisitions, disposals, private equity and public market transactions, for a wide variety of clients including public and private companies, banks, venture capital funds and partnerships, Simon also has considerable client side experience spending a number of years working in-house with Pilkington plc. Simon’s practice covers both UK and International clients and he regularly advises on cross border transactions. He has advised clients on listings on stock markets in the UK, USA, Poland, Belgium, Germany, Hong Kong and Australia. Simon is recognised as one of the leading corporate lawyers in the North West of England. Simon has worked in the life sciences sector for over 20 years. He has a deep understanding of the sector and its key drivers. He has acted for over 35 companies in development capital deals over the last 2 years. He is a member of the Strategic Advisory Board of BIONOW, the cluster organisation for the Biotech Sector in the North of England and a Gold Partner of the Daresbury Campus in Warrington, England, an incubator for Life Sciences and Tech companies. He has also given strategic advice to Manchester University, Liverpool University and Alder Hay Childrens Hospital on their commercialisation strategies.

jacek wolinskiJacek Woliński
Jacek Wolinski has 24 years of professional experience in pharma industry of which over 20 years in Clinical Research Development, working in large multinational companies including biopharma and CRO. Most recent roles include general management, leadership of global clinical teams, business operations and strategic business development in the Contract Research Industry. Currently Senior Director, Strategic Alliance Leadership at IQVIA - managing several global partnerships with emerging biopharma and mid-size pharma companies headquartered in Europe. Holding M.D. degree from Medical School in Lublin, started his professional career in big pharma where he grew from CRA up to Country Manager position at Clinical R&D Unit. Continued his career at Quintiles, first responsible for a growth and delivery of Clinical Operations Department in Poland, next took on Global Delivery Head role for selected therapeutic areas for a strategic big pharma partner. Lecturer in Jagiellonian University, Catholic University of Lublin and Medical School in Lublin for a post graduate courses in clinical research.